Cyprotex PLC Result of AGM (4186Q)

TIDMCRX

RNS Number : 4186Q

Cyprotex PLC

17 June 2015

Cyprotex PLC

("Cyprotex" or the "Company" or the "Group")

Result of AGM

Cyprotex PLC (AIM: CRX), the preclinical ADME-Tox services company, today announces that at the Company's Annual General Meeting held today all the resolutions were duly passed.

For further information:

 
 Cyprotex PLC                         Tel: [phone] 
                                       505 100 
 Dr Anthony Baxter, Chief Executive   [e-mail] 
  Officer                              www.cyprotex.com 
  John Dootson, Chief Financial 
  Officer 
  Mark Warburton, Chief Operating 
  Officer and Legal Counsel 
 
 N+1 Singer (Nomad and broker to      Tel: +44 (0)20 
  Cyprotex)                            7496 3000 
 Shaun Dobson                         [e-mail] 
  Jen Boorer                           [e-mail] 
                                       www.n1singer.com 
 
 

Notes to Editors:

Cyprotex PLC

Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites in Macclesfield, near Manchester in the UK, Watertown, MA and Kalamazoo MI in the US. The Company was established in 1999 and works with more than 1,100 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. The Company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr(R) toxicity prediction technology, predictive modelling using PBPK and QSAR techniques, including Cloe(R) PK for in vivo PK prediction, and a range of skin, ocular and endocrine disruption services. For more information, see www.cyprotex.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGKDLBFEQFLBBE